Anti-Asthmatics and COPD Drugs Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth

This report describes and explains the global anti-asthmatics and COPD drugs market and covers 2015 to 2020, termed the historic period, and 2020 to 2025 termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.

The global anti-asthmatics and COPD drugs market reached a value of nearly $75,376.4 million in 2020, having increased at a compound annual growth rate (CAGR) of 12.7% since 2015. The market is expected to grow from $75,376.4 million in 2020 to $86,436.2 million in 2025 at a rate of 2.8%. The market is then expected to grow at a CAGR of 5.8% from 2025 and reach $114,413.5 million in 2030.

Growth factors in the historic period include increased prevalence of respiratory diseases, increased incidence of tobacco smoking, global warming, geriatric population, emerging markets, new methods for drug discovery, rise in healthcare expenditure. The market was restrained by expiration of patents, political uncertainties.

Going forward increased popularity of e-cigarettes/ vaping, rising obesity levels, technology, large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, increasing consumption of fats will drive the growth in the anti-asthmatics and COPD drugs market. Factors that could hinder the growth of the market in the future include side effects associated with respiratory drugs, reduction in free trade, stringent regulations.

The anti-asthmatics and COPD drugs market is segmented by type of drug class into combination drugs, bronchodilators, monoclonal antibodies, and anti-inflammatory drugs. The combination drugs market was the largest segment of the anti-asthmatics and COPD drugs market segmented by drug class, accounting for 37.4% of the total in 2020. Going forward, the monoclonal antibodies market segment is expected to be the fastest growing segment in the anti-asthmatics and COPD drugs market segmented by drug class, at a CAGR of 6.3% during 2020-2025.

The anti-asthmatics and COPD drugs market is also segmented by type of end user into asthma patients, and COPD patients. The asthma patients end user market was the largest segment of the anti-asthmatics and COPD drugs market segmented by end user, accounting for 61.6% of the total in 2020. Going forward, the COPD patients end user market segment is expected to be the fastest growing segment in the anti-asthmatics and COPD drugs market segmented by end user, at a CAGR of 3.1% during 2020-2025.

The anti-asthmatics and COPD drugs market is also segmented by distribution channel into general pharmacies, hospital pharmacies, and online retailers. The general pharmacies distribution channel market was the largest segment of the anti-asthmatics and COPD drugs market segmented by distribution channel, accounting for 65.3% of the total in 2020. Going forward, the online retailers distribution channel market segment is expected to be the fastest growing segment in the anti-asthmatics and COPD drugs market segmented by distribution channel, at a CAGR of 8.0% during 2020-2025.

The anti-asthmatics and COPD drugs market is also segmented by age group into below 5 years, 5 to 14 years, 15-69 years, and 70+ years. The 15-69 Years age group was the largest segment of the anti-asthmatics and COPD drugs market by age group, accounting for $37,950.2 million or 50.3% of the total market in 2020.

The anti-asthmatics and COPD drugs market is also segmented by therapy into preventive, and curative. The preventive was the largest segment of the anti-asthmatics and COPD drugs market by therapy, accounting for $40,897.4 million or 54.3% of the total market in 2020.

The anti-asthmatics and COPD drugs market is also segmented by route of administration into inhaled, intravenous and subcutaneous, and oral. The inhaled route of administration was the largest segment of the anti-asthmatics and COPD drugs market by route of administration, accounting for $55,104.4 million or 73.1% of the total market in 2020.

The anti-asthmatics and COPD drugs market is also segmented by prescription into prescription, and OTC. The prescription was the largest segment of the anti-asthmatics and COPD drugs market by prescription, accounting for $70,421.1 million or 93.4% of the total market in 2020.

The anti-asthmatics and COPD drugs market is also segmented by drug type into branded, and generics. The branded was the largest segment of the anti-asthmatics and COPD drugs market by drug type, accounting for $72,029.6 million or 95.6% of the total market in 2019.

North America was the largest region in the anti-asthmatics and COPD drugs market, accounting for 47.1% of the total in 2020. It was followed by the Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the anti-asthmatics and COPD drugs market will be Asia-Pacific and Middle East where growth will be at CAGRs of 6.6% and 4.1% respectively during 2020-2025. These will be followed by Africa and North America, where the markets are expected to register CAGRs of 2.9% and 1.8% respectively during 2020-2025.

The unprecedented outbreak of coronavirus has caused a surge in demand for essential pharmaceutical drugs, some bronchodilators, and medical devices including anti-asthmatics and COPD drugs. With governments across the world advising people to stay indoors and practice social distancing, to reduce the spread of the pandemic, individuals are hoarding these medications. This has created a sudden rise in demand for anti-asthmatics and COPD drugs. Anti-asthmatics and COPD drug companies should closely monitor the situation and increase supply of essential medicines and other medical devices for 3 to 6 months. Additionally, some anti-asthmatics and COPD drugs such as albuterol are being used in the treatment of COVID-19. In the wake of the pandemic, companies should focus on modifying their supply chain activities to maximize the output to keep up with the rising demand for these drugs.

The anti-asthmatics and COPD drugs market is slightly consolidated, with a small number of large players. The top ten competitors in the market made up to 33.96% of the total market in 2020. Major players in the market include GlaxoSmithKline plc., AstraZeneca plc., Boehringer-Ingelheim GmbH, F. Hoffmann-La Roche Ltd and Novartis AG.

The top growth potential in the anti-asthmatics and COPD drugs market by drug class will arise in monoclonal antibodies market, which will gain $5,055.64 million of global annual sales by 2025. The top growth potential in the anti-asthmatics and COPD drugs market by end user will arise in the asthma patients market, which will gain $6,249.5 million of global annual sales by 2025. The top growth potential in the anti-asthmatics and COPD drugs market by distribution channel will arise in general pharmacies market, which will gain $4,863.6 million of global annual sales by 2025. The anti-asthmatics and COPD drugs market size will gain the most in the China’s anti-asthmatics and COPD drugs market at $4,273.5 million.

Market-trend-based strategies for the anti-asthmatics and COPD drugs include companies in the anti-asthmatics and COPD drugs market should invest in developing probiotic drugs for asthma to offer a full range of available treatments, developing anti-IL-5 drugs to expand their business portfolio, launching new innovative products to focus on establishing their market position and sustain their position among intense competition in the market, invest more in developing bioelectric medicines to improve asthma care, focus on increasing the number of collaborations to expand their business portfolio, explore opportunities in personalized medicine to counter the intense competition and provide customized treatment to individuals, invest in aerosol respiratory drugs for better efficacy, investing in biomarkers to produce more effective drugs in a smaller time frame, focus efforts on investing in generic drugs to counter the intense competition, developing combination drugs to offer better result, developing biologics to capitalize on the growing demand for biologics.

Player-adopted strategies in the anti-asthmatics and COPD drugs industry include GlaxoSmithKline’s growth strategy aims at investing more in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers, and consumers. Improving GSK’s pipeline of new medicines remains the first priority of the investment. AstraZeneca plc’s growth strategy aims at strengthening its anti-asthmatics and COPD drugs business through the expansion of its product portfolio. Boehringer Ingelheim’s growth strategy aims at expanding its anti-asthmatic drugs business through strategic investments focusing on expansion of its manufacturing operations. F. Hoffmann-La Roche Ltd.’s growth strategy aims at strengthening its position in the anti-asthmatics and COPD drug market by focusing on innovation in existing anti-asthmatics and COPD drugs. Novartis AG’s growth strategy aims at strengthening its position in the anti-asthmatics and COPD drugs market by focusing on the new drug development and continuous innovation.

To take advantage of the opportunities, the publisher recommends the anti-asthmatics and COPD drugs companies to focus on invest in probiotic drugs, focus on bioelectric medicines, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, premium pricing for branded drugs, companies should focus on increasing awareness on asthma and COPD, leveraging medical advice that asthmatics should ensure they consistently stay up to date with preventative medication to protect against COVID-19, target geriatric populations